At Sarcomatrix, we are pioneering a groundbreaking approach in the treatment of muscle diseases, offering first-in-class therapies for muscular dystrophy, cachexia, and sarcopenia. These markets, globally valued in billions, represent significant investment opportunities. Our research and clinical studies strategically pave the way to these lucrative markets, focusing on muscular dystrophies as the gateway. Our proprietary muscle screening platform has enabled us to develop a suite of genetic modifiers. These treatments are not only scientifically robust, with a well-understood mechanism of action, but also protected by strong intellectual property rights. By modulating cellular signaling pathways crucial for integrin production and activation, our therapies promote improved muscle cell adhesion, mobility, and overall health.